AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Platelet Reactivity Modifies the Arterial Thrombotic Effect of Systemic Inflammation: Epidemiological and Proteomic Evidence from the UK Biobank
By Li H, Wang Z, Zhang S
Background: Systemic inflammation predicts arterial thrombotic risk, yet clinical trials of anti-inflammatory therapy show heterogeneous benefit. Platelet reactivity, which exhibits substantial interindividual variation, may represent a key modifier determining whether inflammatory signals are transduced into arterial thrombosis. Hypothesis: Individual platelet reactivity modifies the association between systemic inflammation and arterial, but not venous thrombosis. Methods: Among 318,926 UK Biobank participants free of baseline arterial or venous thrombotic disease, we compared eight inflammatory biomarkers using multivariable Cox regression to identify the strongest predictor of incident arterial thrombosis, defined as a composite of myocardial infarction, ischemic stroke, and peripheral arterial embolism ascertained from hospital records over a median 16-year follow-up. hs-CRP was selected as the primary exposure based on superior predictive performance across arterial outcomes. Platelet reactivity was indexed using a previously validated 21-SNP polygenic score (PRS; high reactivity: PRS ≥75th percentile). Effect modification of the hs-CRP-arterial thrombosis association by platelet reactivity PRS was evaluated using multiplicative interaction terms in stratified Cox models, with venous thromboembolism serving as a negative control outcome to assess arterial specificity. Among 48,656 participants with Olink proteomics data, candidate proteins were identified through sequential hs-CRP-associated linear regression and thrombosis-associated Cox modeling, with PCSK9 emerging as a key candidate at the intersection of inflammatory and platelet activation pathways. Results: hs-CRP demonstrated the strongest association with arterial thrombosis (HR per SD 1.104, 95%CI 1.086-1.122, P<0.001) with a significant nonlinear dose-response relationship (P-nonlinear<0.001). High platelet reactivity was associated with elevated arterial thrombosis risk only in the high inflammation stratum (hs-CRP ≥2 mg/L; HR 1.082, 95%CI 1.018-1.149, P=0.011; P-interaction=0.017), with a similar pattern for myocardial infarction (HR 1.095, P-interaction=0.010). No interaction was observed for venous thromboembolism (P-interaction=0.280). Proteomic analysis identified PCSK9 as a key candidate protein at the intersection of inflammatory and platelet activation pathways, with arterial specificity. Conclusions: Platelet reactivity selectively amplifies inflammation-driven arterial thrombosis risk in individuals with elevated hs-CRP, with no parallel effect on venous thrombosis. PCSK9 emerged as a biologically plausible candidate linking systemic inflammation to arterial thrombotic pathways. These findings suggest platelet reactivity may help identify individuals most likely to benefit from anti-inflammatory therapy.